BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

Ciprian TomuleasaDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania;Research Center for Functional Genomics and Translational Medicine, Cluj Napoca, RomaniaCorrespondence[email protected] [email protected]

Delia DimaDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Ioana FrincDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Mariana PatiuDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Bobe PetrushevResearch Center for Functional Genomics and Translational Medicine, Cluj Napoca, Romania

Andrei CucuianuDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania;Department of Hematology, Iuliu Hatieganu University, Cluj Napoca, Romania

Ioana Berindan-NeagoeResearch Center for Functional Genomics and Translational Medicine, Cluj Napoca, Romania;Department of Genetics, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

show all

References

Jurcek T, Razga F, Mazancova P, et al. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia. Leuk Lymphoma 2014 Feb 6. [Epub ahead of pirnt]
PubMed Web of Science ®Google Scholar
Gleixner KV, Ferenc V, Peter B, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010;70: 1513–1523.
PubMed Web of Science ®Google Scholar
O’Brien SG, Guilhot F, Larson RA, et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
PubMed Web of Science ®Google Scholar
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date